Novo Nordisk shares rose Wednesday after fourth-quarter earnings beat Wall Street's estimates, 2025 forecast came in line ...

Novo Nordisk stock rose Wednesday after the drugmaker reported quarterly earnings above analysts’ expectations, but forecast ...

In a 72-week study, Zepbound's mean weight loss was 20.2%, while Wegovy's was 13.7%. Amycretin did better in half the time. Novo Nordisk faces at least two issues in the anti-obesity space.

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply ... next-generation weight loss drugs CagriSema and amycretin are also in focus. It's been a rocky few months for Novo Nordisk.